348640-06-2

Basic information

• Product Name: 4-Bromo-7-azaindole
• Synonyms: 1H-PYRROLO[2,3-B]PYRIDINE, 4-BROMO-;4-BROMO-7-AZAINDOLE;4-BROMO-1H-PYRROLO[2,3-B]PYRIDINE;4-broMo-1H-pyrrolo[2;4-BroMo-7-Azaindol;4-Bromo-1H-pyrrolo-[2,3]pyridine;348640-06-2
• CAS NO: 348640-06-2
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• EINECS: 1592732-453-0
• Product Categories: CHIRAL CHEMICALS;Azaindoles;6
• Mol File: 348640-06-2.mol

Chemical Properties

• Melting Point: 178-183℃
• Appearance: Yellow to orange/Solid
• Density: 1.771 g/cm³
• Refractive Index: 1.728
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 12.95±0.40(Predicted)
• CAS DataBase Reference: 4-Bromo-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-7-azaindole(348640-06-2)
• EPA Substance Registry System: 4-Bromo-7-azaindole(348640-06-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 348640-06-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-7-azaindole is used as an important organic intermediate for the synthesis of substituted azaindole products. These products are crucial in the development of new pharmaceuticals, particularly those targeting specific biological pathways or receptors.
Used in Chemical Synthesis:
4-Bromo-7-azaindole is used as a chemical reagent in the synthesis of tyrosine kinase inhibitors. Tyrosine kinase inhibitors are a class of drugs that block the activity of tyrosine kinases, which are enzymes involved in cell signaling and growth. These inhibitors are used to treat various types of cancer by preventing the uncontrolled growth of cancer cells.

InChI:InChI=1/C7H5BrN2/c8-6-2-4-10-7-5(6)1-3-9-7/h1-4H,(H,9,10)

Upstream product

• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 7143-01-3 Methanesulfonic anhydride 
• 271-63-6 7-Azaindole 

Downstream Products

• 640735-24-6 4-bromo-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine 
• 348640-07-3 4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 943323-63-5 4-bromo-3-nitro-1H-pyrrolo[2,3-b]pyridine 
• 943323-92-0 4-bromo-3-chloro-1H-pyrrolo[2,3-b]pyridine 
• 1067887-43-7 phenyl(1H-pyrrolo[2,3-b]pyridin-4-yl)methanol 
• 1228014-35-4 4-bromopyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester 
• 942919-30-4 4-[1-(1,1-dimethylethyl)-5-(4-nitrophenyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine 
• 942919-32-6 4-[3-(4-nitrophenyl)-1-(2-propen-1-yl)-1H-pyrazol-4-yl]-1Hpyrrolo[2,3-b]pyridine 
• 942920-30-1 [3-(4-nitrophenyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]acetic acid 
• 942920-26-5 4-[1-{[4-(methyloxy)phenyl]methyl}-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine 
• 1234616-25-1 4-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine 
• 1253410-44-4 4-methyl-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenylamine 
• 1248587-58-7 3-(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperazin-1-yl)phenol 
• 1014613-05-8 1-(benzenesulfonyl)-4-bromo-2-methyl-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

5 - thiazole amides and biological applications

The invention relates to a 5-thiazole amide compound and biology application thereof. The 5-thiazole amide compound has a general formula (I) described in the specification and is used for targeting an AKT/PKB kinase (ATP binding site). Experiments prove that a thiazole amide AKT inhibitor can remarkably inhibit the activity of the AKT kinase in vitro and has strong proliferation inhibition function on various tumor cells with high AKT activity, which indicate that the 5-thiazole amide compound can be used for preparing drugs for resisting tumors.

Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition

A solution-phase parallel synthesis of triazole-derived ruxolitinib analogues was developed in the current study. The method employs copper-catalyzed azide-alkyne cycloaddition to build up the central triazole template. Product isolation by precipitation

New thiazole carboxamides as potent inhibitors of Akt kinases

A new series of 2-substituted thiazole carboxamides were identified as potent pan inhibitors against all three isoforms of Akt (Akt1, Akt2 and Akt3) by systematic optimization of weak screening hit N-(1-amino-3-phenylpropan-2-yl)- 2-phenylthiazole-5-carboxamide (1). One of the most potent compounds, 5m, inhibited the kinase activities of Akt1, Akt2 and Akt3 with IC50 values of 25, 196 and 24 nM, respectively. The compound also potently inhibited the phosphorylation of downstream MDM2 and GSK3β proteins, and displayed strongly antiproliferative activity in prostate cancer cells. The inhibitors might serve as lead compounds for further development of novel effective anticancer agents.

CHEMICAL COMPOUNDS

There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 3-substituted-1H-indole, 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY

Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

PYRROLOPYRIDINES AS KINASE INHIBITORS

Compounds of Formula (I) are useful for inhibition of CHKl and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula 1: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of for